Ch Biotech R&D (正瀚) reported 2025 consolidated revenue of NT$1.819 billion (+11.21% YoY), marking its fifth consecutive record-breaking year. With strong orders from North America, the company expects a record-high Q1 2026 as it enters the traditional peak season.

Strategic Roadmap:

• Global Footprint: While US sales remain stable, new overseas markets showed strong momentum in 2025. Sinon plans to establish physical operations in Europe this year to address diverse farm structures.
• R&D Focus: The company continues to develop high-value, high-efficiency products in Peptide Technology and Plant Growth Regulators (PGR). Its solutions align with the EU’s aggressive push for agricultural transformation and net-zero sustainability.

Resource: 正瀚2025年營收18.19億 年增11.21％ 連五年創新高